Department of Surgical Pathology, Holycross Cancer Center, Kielce, Poland.
Endocrinology Clinic, Holycross Cancer Center, Artwińskiego 3 Street, 25-734, Kielce, Poland.
Endocr Pathol. 2020 Jun;31(2):143-149. doi: 10.1007/s12022-020-09619-0.
In 2016, Nikiforov et al. (JAMA Oncol 2:1023-1029, 2016) proposed replacing the term "non-invasive encapsulated follicular variant of papillary thyroid carcinoma" (FVPTC) with the term "non-invasive follicular thyroid neoplasm with papillary-like nuclear features" (NIFTP). In 2018, to avoid the misdiagnosis of papillary thyroid cancer as NIFTP, the authors proposed changes to the criteria for NIFTP classification. Some previous studies evaluated the impact of NIFTP on the risk of malignancy (ROM) in the fine-needle aspiration cytology (FNAC) diagnostic categories according to the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). However, little is known about the influence of an NIFTP diagnosis on ROM on the basis of the revised criteria. The aim of this study was to assess the influence of NIFTP on ROM using the revised diagnostic criteria. The present study included 998 thyroid nodules that were diagnosed and resected at the same medical center. All specimens with a diagnosis of cancer were reviewed to identify NIFTP according to the revised 2018 criteria. Additionally, molecular diagnostics were performed to detect the BRAF p.V600E mutation and TERT promoter mutations in all the NIFTP cases. The number of cases that met the revised criteria was determined, and the ROM was calculated in each of the FNAC diagnostic categories. Only five cases (2.3% of all papillary thyroid carcinoma diagnoses) were considered NIFTP, according to the 2018 criteria. With respect to the FNAC category, one case was a follicular neoplasm or suspicious for a follicular neoplasm (FN/SFN), three cases were suspicious for malignancy (SM), and one case was malignant (M). The ROM decreased in each of the Bethesda categories (0.7% in FN/SFN, 4.3% in SM, and 0.5% in M) when a diagnosis of NIFTP was taken into account. These reductions were not statistically significant. These data indicate that the NIFTP entity has very little impact on ROM for the diagnostic categories of the Bethesda system.
2016 年,Nikiforov 等人(JAMA Oncol 2:1023-1029,2016)提出用“非侵袭性包裹滤泡型甲状腺乳头状癌”(FVPTC)取代“具有乳头状核特征的非侵袭性滤泡性甲状腺肿瘤”(NIFTP)。2018 年,为避免将甲状腺乳头状癌误诊为 NIFTP,作者提出了 NIFTP 分类标准的修改。一些先前的研究根据甲状腺细胞病理学报告的 Bethesda 系统(TBSRTC)评估了 NIFTP 对细针抽吸细胞学(FNAC)诊断分类中恶性肿瘤风险(ROM)的影响。然而,根据修订后的标准,关于 NIFTP 诊断对 ROM 的影响知之甚少。本研究旨在评估使用修订后的诊断标准,NIFTP 对 ROM 的影响。本研究纳入了在同一医疗中心诊断和切除的 998 个甲状腺结节。根据修订后的 2018 标准,对所有诊断为癌症的标本进行了重新评估,以确定 NIFTP。此外,对所有 NIFTP 病例进行了 BRAF p.V600E 突变和 TERT 启动子突变的分子诊断。确定了符合修订标准的病例数,并计算了每个 FNAC 诊断类别中的 ROM。根据 2018 年的标准,只有 5 例(所有甲状腺乳头状癌诊断的 2.3%)被认为是 NIFTP。就 FNAC 类别而言,1 例为滤泡性肿瘤或滤泡性肿瘤可疑(FN/SFN),3 例为疑似恶性(SM),1 例为恶性(M)。当考虑到 NIFTP 诊断时,贝塞斯达分类中的每个 ROM 都有所降低(FN/SFN 为 0.7%,SM 为 4.3%,M 为 0.5%)。这些降低没有统计学意义。这些数据表明,NIFTP 实体对贝塞斯达系统的诊断类别中的 ROM 影响很小。